Press "Enter" to skip to content

Osimertinib plus intermittent selumetinib shows preliminary activity in EGFR -mutated lung cancer – Healio

admin 0

Osimertinib plus intermittent selumetinib shows preliminary activity in EGFR -mutated lung cancer  Healio

ATLANTA — Osimertinib plus intermittent selumetinib demonstrated preliminary antitumor activity and acceptable toxicity in patients with EGFR-mutated …

“lung cancer” – Google News

(Visited 4 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *